Limits...
Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats.

Yan J, Yang X, Han D, Feng J - Mol Med Rep (2016)

Bottom Line: Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown.Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents.The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, The Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.

ABSTRACT
Multiple sclerosis (MS) is an inflammatory autoimmune neurodegenerative disease, which features focal demyelination and inflammatory cell infiltration of the brain and the spinal cord. Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown. The current study was designed to investigate the potential therapeutic function of TSIIA on MS in the experimental autoimmune encephalomyelitis (EAE) rat model. In comparison to the vehicle control group, the TSIIA‑treated groups showed notably improved clinical symptoms and pathological changes, including central nervous system inflammatory cell infiltration and demyelination. Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents. Furthermore, TSIIA was also shown to downregulate interleukin (IL)‑17 and IL‑23 levels in the brain and serum of EAE rats. The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

No MeSH data available.


Related in: MedlinePlus

Immunohistochemistry of IL-17 and IL-23. (A–D) IL-17; (E–H) IL-23; Magnification, ×200. (A and E) Naive group; (B and F) vehicle group; (C and G) TSIIA-L group; and (D and H) TSIIA-H group. Quantitative analysis of (I) IL-17 and (J) IL-23 was conducted. Values are presented as the mean ± standard deviation (n=10 per group). ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group or n (not significant) between the TSIIA-L and TSIIA-H groups. IOD, integral optical density; IL, interleukin; TSIIA, Tanshinone IIA; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940100&req=5

f5-mmr-14-02-1601: Immunohistochemistry of IL-17 and IL-23. (A–D) IL-17; (E–H) IL-23; Magnification, ×200. (A and E) Naive group; (B and F) vehicle group; (C and G) TSIIA-L group; and (D and H) TSIIA-H group. Quantitative analysis of (I) IL-17 and (J) IL-23 was conducted. Values are presented as the mean ± standard deviation (n=10 per group). ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group or n (not significant) between the TSIIA-L and TSIIA-H groups. IOD, integral optical density; IL, interleukin; TSIIA, Tanshinone IIA; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.

Mentions: Expression of the inflammatory cytokines, IL-17 and IL-23, is usually increased in the CNS in EAE. To assess whether TSIIA exerts anti-inflammatory activity in EAE in vivo, its effects on IL-23 and IL-17 levels in the brain were determined using immunohistochemistry. Compared with the naive group, expression of IL-17 and IL-23 in the vehicle groups was significantly increased (P<0.01). Compared with the vehicle group, TSIIA treatment significantly induced a reduction in IL-17 and IL-23 expression (P<0.01). However, there were no significant differences between the two treatment groups (P>0.05; Fig. 5). The effects of TSIIA on these indicators were further confirmed by quantitative western blot analysis (P<0.01), and significant differences were identified between the TSIIA-L and TSIIA-H groups in IL-17 (P<0.01) and IL-23 (P<0.05) expression (Fig. 4 A, E and F).


Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats.

Yan J, Yang X, Han D, Feng J - Mol Med Rep (2016)

Immunohistochemistry of IL-17 and IL-23. (A–D) IL-17; (E–H) IL-23; Magnification, ×200. (A and E) Naive group; (B and F) vehicle group; (C and G) TSIIA-L group; and (D and H) TSIIA-H group. Quantitative analysis of (I) IL-17 and (J) IL-23 was conducted. Values are presented as the mean ± standard deviation (n=10 per group). ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group or n (not significant) between the TSIIA-L and TSIIA-H groups. IOD, integral optical density; IL, interleukin; TSIIA, Tanshinone IIA; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940100&req=5

f5-mmr-14-02-1601: Immunohistochemistry of IL-17 and IL-23. (A–D) IL-17; (E–H) IL-23; Magnification, ×200. (A and E) Naive group; (B and F) vehicle group; (C and G) TSIIA-L group; and (D and H) TSIIA-H group. Quantitative analysis of (I) IL-17 and (J) IL-23 was conducted. Values are presented as the mean ± standard deviation (n=10 per group). ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group or n (not significant) between the TSIIA-L and TSIIA-H groups. IOD, integral optical density; IL, interleukin; TSIIA, Tanshinone IIA; TSIIA-L, TSIIA low dose; TSIIA-H, TSIIA high dose.
Mentions: Expression of the inflammatory cytokines, IL-17 and IL-23, is usually increased in the CNS in EAE. To assess whether TSIIA exerts anti-inflammatory activity in EAE in vivo, its effects on IL-23 and IL-17 levels in the brain were determined using immunohistochemistry. Compared with the naive group, expression of IL-17 and IL-23 in the vehicle groups was significantly increased (P<0.01). Compared with the vehicle group, TSIIA treatment significantly induced a reduction in IL-17 and IL-23 expression (P<0.01). However, there were no significant differences between the two treatment groups (P>0.05; Fig. 5). The effects of TSIIA on these indicators were further confirmed by quantitative western blot analysis (P<0.01), and significant differences were identified between the TSIIA-L and TSIIA-H groups in IL-17 (P<0.01) and IL-23 (P<0.05) expression (Fig. 4 A, E and F).

Bottom Line: Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown.Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents.The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, The Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.

ABSTRACT
Multiple sclerosis (MS) is an inflammatory autoimmune neurodegenerative disease, which features focal demyelination and inflammatory cell infiltration of the brain and the spinal cord. Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown. The current study was designed to investigate the potential therapeutic function of TSIIA on MS in the experimental autoimmune encephalomyelitis (EAE) rat model. In comparison to the vehicle control group, the TSIIA‑treated groups showed notably improved clinical symptoms and pathological changes, including central nervous system inflammatory cell infiltration and demyelination. Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents. Furthermore, TSIIA was also shown to downregulate interleukin (IL)‑17 and IL‑23 levels in the brain and serum of EAE rats. The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

No MeSH data available.


Related in: MedlinePlus